Mon 6/18/2018 16:58 ET
DJIA24987.47103.010.41%TELCO155.413.001.93%GOLD1280.802.310.18%Shanghai3021.9022.060.73%
S&P 5002773.875.830.21%BANKS468.790.840.18%OIL65.680.831.26%BITCOIN6729.16282.624.20%
NASDAQ7747.030.770.01%PHARM504.115.341.06%US/EU1.170.000.26%Futures2777.756.750.24%
Welcome Stranger!  Please sign up or log in to enable additional features.Sign Up | Mail | Log In
Forum - Bond Market & USD Collapse (vTv Therapeutics Inc - VTVT)    Welcome to the Economic Collapse Forum

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add VTVT
  
From: Lowfloatmagic (Rep: 12)Date: 04/12/2018 11:04
Forum: Bond Market & USD Collapse - Msg #179 - List VTVT msgs Thread #674003148 (Rec: 0)
Clinical Data Should have Positive Phase 2 Results Coming soon
TTP399 has been studied in a series of phase 1 and phase 2 clinical trials. In all studies, TTP399 has been safe and well tolerated, with no increased incidence of hypoglycemia compared to placebo. The results of these trials, suggest that our approach to glucokinase activation will avoid safety and tolerability issues associated with other GKAs, such as activation of glucokinase in the pancreas, stimulation of insulin secretion independent of glucose, hypoglycemia, increased lipids and liver toxicity. Further, we believe that TTP399 will compare favorably with other products in the market, as our trials have indicated that TTP399 may have higher efficacy than competing products, the ability to normalize HbA1c, and no contraindication for renal impairment.

We have completed a Phase 2 clinical trial of TTP399, a randomized, double-blind, parallel-group, placebo-controlled, six-week, multiple dose study in 151 type 2 diabetic patients whose glycemic parameters were not well-controlled on metformin. The trial was designed to assess the pharmacokinetics, pharmacodynamics, safety and tolerability of TTP399 in formulation 1 and was conducted at 11 centers in the United States. Patients were randomized into four arms: TTP399 400 mg BID, TTP399 800 mg QD, TTP399 800 mg BID, and placebo. All patients remained on consistent doses of metformin throughout the trial.

http://www.vtvtherapeutics.com/pipeline/ttp399

What would you like to do? Message: Endorse | Bookmark | Report AbuseUser Lowfloatmagic: Reward | Watch | IgnoreVTVT: Ignore

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add VTVT
  

TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.